The use of genomic technology for assessing health risks associated with chemical exposure has significant potential, but its direct application has proven to be challenging for the toxicology and risk assessment communities. In this study, a method was established for analyzing dose-response microarray data using benchmark dose (BMD) calculations and gene ontology (GO) classification. Gene expression changes in the rat nasal epithelium following acute formaldehyde exposure were used as a case study. The gene expression data were first analyzed using a one-way ANOVA to identify genes that showed significant dose-response behavior. These genes were then fit to a series of four statistical models (linear, second-degree polynomial, third-degree polynomial, and power models) and the least complex model that best described the data was selected. The genes were matched to their associated GO categories, and the average BMD and benchmark dose lower confidence limit (BMDL) were calculated for each GO category. The results were used to identify doses at which individual cellular processes were altered. For the formaldehyde exposures, the BMD estimates for the GO categories related to cell proliferation and DNA damage were similar to those measured in previous studies using cell labeling indices and DNA-protein cross-links and consistent with the BMD estimated for rat nasal tumors. The method represents a significant advance in applying genomic information to risk assessment by allowing a comprehensive survey of molecular changes associated with chemical exposure and providing the capability to identify reference doses at which particular cellular processes are altered.
A major objective of toxicology and chemical risk assessment is to identify permissible exposure levels based on data from human or experimental animal studies together with other relevant scientific information. In the past, the permissible exposure levels were based on doses corresponding to lowest observed adverse effect levels (LOAEL) or no observed adverse effect levels (NOAEL). The LOAEL has been traditionally defined as the first dose producing a statistically significant, adverse change in the response and the NOAEL as the dose preceding the LOAEL. The weakness of this approach is that dose spacing and the experimental sample size can have a dramatic impact on the final NOAEL and LOAEL, and the approach does not account for variability in the estimate of the dose-response or the slope of the dose-response curve. To overcome these limitations, benchmark dose (BMD) analysis was introduced (Crump, 1984) . BMD analysis fits a statistical model to the dose-response data and identifies a dose that causes a defined change in the adverse response. The application of BMD analysis provides several advantages including better use of dose-response information, more appropriate reflection of experimental sample sizes, and the lack of constraint to experimental doses (Filipsson et al., 2003) .
The application of microarray technology in toxicology has proven to be both useful for simultaneously measuring the expression of thousands of genes and challenging with respect to interpreting what changes in these genes mean in relation to the toxic response. The transcriptional changes represent only a snapshot of the state of the cell or tissue and include a complex mix of primary and secondary responses to the chemical treatment (Page et al., 2006) . Previous efforts to interpret these changes have focused on applying standardized functional annotations to each gene involved in the response and identifying whether certain biological processes or molecular functions are over-or underrepresented (Beissbarth and Speed, 2004; Dennis et al., 2003; Khatri et al., 2004; Yu et al., 2006; Zhang et al., 2004) . This approach has been referred to as a gene ontology (GO) enrichment analysis and allows large lists of transcriptional alterations to be distilled down into changes in cellular processes such as the immune response, DNA repair, or apoptosis.
Although GO enrichment analyses provide insights into what biological processes are altered, this type of analysis has been primarily applied to studies designed to examine only a single experimental variable at a time. The informatic tools available for analyzing higher dimensional data such as doseresponse and time course studies have so far been limited. Recently, Yu et al. (2006) introduced an approach to apply GO analysis to dose-response studies. Using this approach, the doseresponse changes in the various functional categories are summarized using EC 50 values allowing the identification of cellular processes that have different dose-response characteristics (Yu et al., 2006) . The approach represents a significant contribution for analyzing dose-response data within toxicology. To broadly apply genomic studies to chemical risk assessment, the functional changes must be linked to a defined increase in risk through a more rigorous statistical approach, such as BMD.
Formaldehyde is a major industrial chemical and is widely used as a raw material in the manufacture of synthetic resins, lubricants, adhesives, and fertilizers. In 1992, 8.3 billion pounds were produced within the United States and its production ranked 22nd overall (ATSDR, 1999) . Among the acute effects elicited by formaldehyde, sensory irritation has been reported to occur at less than 1 ppm in humans and 2 ppm in animals (Arts et al., 2006) . Following longer term exposures, regenerative cell proliferation and DNA-protein cross-links have been observed together with an increased incidence of nasal squamous cell carcinomas in rodent models at doses ranging from 2 to 15 ppm (Casanova et al., 1989; McGregor et al., 2006; Monticello et al., 1996) . In these studies, the dosedependent contribution of genotoxicity versus regenerative cell proliferation in the carcinogenic process remains controversial. The International Agency for Research on Cancer (IARC) has listed formaldehyde as a human carcinogen due to increased risk of nasopharyngeal cancer (IARC, 2006 ). An increased incidence of myeloid leukemia and sinonasal cancer has also been observed in epidemiologic studies, but the level of evidence has not been sufficient for causal association with formaldehyde exposure (IARC, 2006) .
The objective of this study was to develop a method that integrates BMD calculations with GO classification analysis in the examination of genomic dose-response data. The combination of microarray technology with these analysis methods results in a unique risk assessment tool that provides both a comprehensive survey of molecular changes following chemical exposure and dose estimates at which different cellular processes are altered based on a defined increase in risk. A case study for application of the method is provided using gene expression changes in the rat nasal epithelium following acute formaldehyde exposure. Despite the initial focus on formaldehyde, the method should serve as a template for a broader application of genomic data to chemical risk assessment.
MATERIALS AND METHODS
Animals and treatment. Male F344/NCrl rats were obtained from Charles River Laboratories (Wilmington, MA) at 6 weeks of age. Upon receipt, the rats were randomized by weight and divided into treatment groups. Following randomization, rats were acclimated for a period of 2 weeks and exposures began at 8 weeks of age. Rats were housed in 8-m 3 stainless steel and glass inhalation chambers. Temperature was kept between 17.8 and 26.1°C, and humidity was maintained at 30-70%. Lighting was kept on a standard 12-h light/dark cycle, and all animals were given access to NIH-07 certified diet (Zeigler Brothers Corp., Gardners, PA) and water ad libitum except during the 6-h formaldehyde exposure when food was withheld. Animal use in this study was approved by the Institutional Animal Use and Care Committee of CIIT Centers for Health Research and was conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. Animals were housed in fully accredited American Association for Accreditation of Laboratory Animal Care facilities.
Animals were exposed to target concentrations of 0.7, 2.0, 6.0, and 15.0 ppm (0.86, 2.46, 7.38, 18.5 mg/m 3 ) formaldehyde for a period of 6 h. Previous studies have demonstrated increased regenerative cell proliferation and DNAprotein cross-links following a 6-h exposure (Casanova et al., 1989; Monticello et al., 1991) . Control animals were exposed to filtered air only. The exposure atmospheres were generated by thermal depolymerization of paraformaldehyde (lot#: 035K1609; Sigma-Aldrich Corp., St Louis, MO). The concentration of formaldehyde was monitored using a calibrated infrared analyzer (Miran 1A, Foxboro Instruments, Foxboro, MA). Airflow was maintained at 12-15 air changes per hour. For formaldehyde-treated groups, a total of eight animals per dose level were used for histopathology and four animals per dose level were used for microarray analysis. For air-exposed control animals, a total of 16 animals were used for histopathology and eight animals were used for microarray analysis.
Following the 6-h exposure, the rats were euthanized by exsanguination following an ip dose of sodium pentobarbital (Abbott Laboratories Corp., Chicago, IL). In animals exposed for histopathology, the nasal cavity was flushed retrograde with 10% neutral buffered formalin and fixed for 72 h. Following fixation, the noses were rinsed and decalcified (Immunocal, Decal Chemical Corp., Tallman, NY) for 3-4 days. The decalcified noses were gross trimmed, embedded in paraffin, sectioned at 5 lm, and stained with hematoxylin and eosin. Histological changes in the level II region were assessed by an accredited pathologist. In animals exposed for microarray analysis, the noses were dissected to isolate the level II region (Monticello et al., 1996) . The maxillo turbinate and olfactory epithelium from this region were discarded. and the lateral meatus and nasoturbinate were retained for further processing. The dissected nasal sections were then rinsed with cold phosphate-buffered saline to remove the blood. After rinsing, a 5 ml buffered mixture of proteases (collagenase, 80 U/ml, Sigma-Aldrich; pronase, 10 mg/ml, Sigma-Aldrich; HEPES, 0.1M) in Hams F12 medium (Invitrogen, Inc., Carlsbad, CA) was added to each nose and incubated at 37°C for 40 min to remove the epithelial cell layer. The epithelial cells acquired from this section of the nose consisted primarily of transitional epithelium with some respiratory epithelium. Following incubation, the mixtures were vortexed, and the resulting cell suspensions were collected in clean centrifuge tubes. The cell suspensions were centrifuged (200 3 g, 10 min, 10°C), and the cell pellet was resuspended in 50 ll PBS and 200 ll RNAlater (Ambion Corp., Austin, TX).
Gene expression microarray measurements and initial selection of responsive genes. Cell suspensions were centrifuged for 10 min (16,000 3 g), and total RNA was isolated from the cell pellet using the RNeasy Micro RNA isolation kit (Qiagen Corp., Valencia, CA). The cell pellet was resuspended with 350 ll of lysis buffer containing b-mercaptoethanol. Each sample was homogenized and processed through the tissue protocol with an elution volume of 17 ll. The quantity of RNA was measured spectrophotometrically (NanoDrop ND-1000, NanoDrop Technologies, Inc., Montchanin, DE), and the integrity of the RNA was verified with the Agilent 2100 Bioanalyzer (Palo Alto, CA). Double-stranded cDNA was synthesized from 2 lg of total RNA using the One-Cycle cDNA synthesis kit (Affymetrix Corp., Santa Clara, CA). Biotinlabeled cRNA was transcribed from the cDNA using the GeneChip IVT Labeling Kit (Affymetrix). Fifteen micrograms of labeled cRNA was ESTIMATING BENCHMARK DOSES FOR GENOMIC DATA 241 fragmented and hybridized to an Affymetrix Rat Genome 230 2.0 array for 16 h at 45°C. The hybridized array was washed using the GeneChip Fluidics Station 450 and scanned using a GeneChip 3000 scanner. The gene expression results have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (accession no.: GSE7002).
The data analysis steps associated with the method are outlined in Figure 1 . Initially, microarray data were processed using robust multi-array average normalization with a log 2 transformation (Irizarry et al., 2003) . The log 2 -transformed data were analyzed using a one-way ANOVA to identify probe sets on the array for which there was a difference in expression associated with treatment (dose). Probability values were adjusted for multiple comparisons using a false discovery rate of 5% (Benjamini and Hochberg, 1995) . Only probe sets identified as significant based on the ANOVA were used in the subsequent BMD analysis. This initial probe set selection was necessary to reduce the computational requirements in the BMD calculations. BMD calculations and model selection. The probe sets identified by the ANOVA were fit as continuous data to a series of four different dose-response models-linear, second-degree polynomial, third-degree polynomial, and power models. Each probe set was fit independently using the BMDExpress software program (http://sourceforge.net/projects/bmdexpress/). The parameter settings used for the software are provided as supplemental material (Supplementary Table 1) . Each model was run assuming constant variance, and the benchmark response (BMR) factor was set to 1.349 multiplied by the SD in the control animals. To derive this value, a normal distribution was assumed for control animals, and it was assumed, a priori, that the transcriptional response could occur in either tail, with a 1% change of that occurring in the absence of exposure (0.5% in each tail). A BMR of 1.349 is the amount required to shift the mean transcriptional response of the control distribution such that the treated distribution contains 11% in a single tail, i.e., a 10% increase over the assume background rate of response (Fig. 2) . Finally, each of the four models was run twice-once with the direction of the transcriptional response in the positive and once in the negative direction. The direction of the transcriptional response with the lowest BMD was selected for further analysis. The requirement to run each model twice was due to limitations in the BMDS software used to do the curve fitting. Unless stipulated, the BMDS software will automatically choose the direction of the response based on the direction observed at the highest dose. For probe sets that demonstrated nonmonotonic behavior, any significant change at the lower doses would be ignored in favor of the direction of the transcriptional response at the highest dose.
For model selection, a nested likelihood ratio test was performed on the linear, second-degree polynomial, third-degree polynomial models. If the more complex model provided a significantly improved fit ( p < 0.05), the more complex model was selected. If the more complex model did not provide a significantly improved fit ( p 0.05), the simpler model was selected (Posada and Buckley, 2004) . The Akaike information criterion (AIC) for the selected polynomial model was then compared with the AIC for the power model. The model with the lowest AIC (Akaike, 1973) was selected as the final model and was used to calculate a BMD and benchmark dose lower confidence limit (BMDL). To avoid model extrapolation, probe sets with a BMD value greater than the highest dose (i.e., 15 ppm) were removed from further analysis.
GO analysis and calculation of summary values. The gene annotations and GO classifications for all probe sets on the Affymetrix Rat Genome 230 2.0 array were downloaded from the Affymetrix Web site. Affymetrix probe sets that demonstrated significant dose-response behavior and had a BMD < 15 ppm were converted into unique genes based on their NCBI Entrez Gene ID. When two or more probe sets were associated with a single gene, the BMDs and BMDLs for the individual probe sets were averaged to obtain a single BMD and BMDL. The Entrez Gene identifiers were then matched to their corresponding FIG. 1. A flow chart outlining the stepwise analysis of dose-response microarray data using BMD calculations and GO classification analysis. The methodology provides dose estimates at which different cellular processes are altered at a defined increase in risk based on expression levels in the untreated controls.
FIG.
2. An illustration of the rationale for selection of the BMR. The BMR was derived by assuming a normal distribution in control animals with 0.5% in both tails (a ¼ 1% total). A value of 1.349 multiplied by the SD in the control animals is the amount required to shift the mean response of the control distribution such that the treated distribution contains 11% in a single tail.
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biological process and molecular function GO categories. GO categories with less than three genes were removed from the analysis. The three-gene cut-off was based on the minimum number required to define a mean and SD for the category.
In this study, there was no attempt to distinguish between adverse and nonadverse changes in gene expression within the various GO categories. The discrimination between adverse and nonadverse effects has been the subject of considerable debate within toxicology (Foster and McIntyre, 2002; Karbe et al., 2002; Lewis et al., 2002) , and this discrimination can be even more difficult when analyzing gene expression changes. Therefore, all transcriptional changes that were significantly different from control animals were assumed to be adverse, and summary values for all GO categories were reported.
RESULTS

Formaldehyde Exposure and Histopathological Analysis
Rats were exposed for 6 h via whole-body inhalation to four concentrations of formaldehyde (0.7, 2.0, 6.0, and 15.0 ppm) plus an air control. The histopathological changes were relatively minor with only inflammatory infiltrate observed in seven out of eight animals at the 15.0 ppm concentration. No other histopathological changes were observed.
Dose-Response Microarray Measurements and Initial Gene Selection
Measurement of gene expression changes was performed on epithelial cell suspensions isolated from the level II region of individual rat noses. The cell suspensions contained primarily transitional epithelium with some respiratory epithelium. In addition, this section of the nose contained the regions of high formaldehyde flux (Kimbell et al., 1993) and nasal tumors in chronic exposure studies (Kerns et al., 1983; Monticello et al., 1991 Monticello et al., , 1996 Morgan et al., 1986) . For the initial gene selection, a one-way ANOVA was used to identify probe sets on the array that were significantly changed with dose. A total of 4263 probe sets were identified at a false discovery rate of 5%.
BMD Calculations and Model Selection
Using the probe sets identified by the ANOVA, four different statistical models (linear, second-degree polynomial, thirddegree polynomial, and power models) were fit to the data, and the model that best described the data with the least amount of complexity was selected. Following model selection, a total of 108 probe sets had a BMD greater than the highest dose (15.0 ppm) and were removed from the analysis to avoid model extrapolation. The model breakdown among the final probe sets was 38.8% linear model, 48.3% second-degree polynomial model, 12.4% third-degree polynomial model, and 0.4% power model. Based on the likelihood ratio test performed by the BMDS software, the dose-response behaviors for greater than 80% of the probe sets were adequately described by the final selected model (p > 0.05) (Fig. 3 ). An example of each model together with their goodness-of-fit p value is provided in Figure 4 .
GO Analysis and Calculation of Summary Values
The final genes from the BMD analysis were assigned into groups based on their GO classifications. The genes were ESTIMATING BENCHMARK DOSES FOR GENOMIC DATA grouped by both their biological process categories (e.g., cell division, DNA repair, cell proliferation, or apoptosis) and their molecular function categories (e.g., lipase activity, heparin binding, protein kinase activity, or cytokine activity). The GO categories with the lowest average BMD values are presented in Tables 1 and 2 . For comparison, the average BMD for all genes with significant dose-response behavior was 6.42 ± 4.16 ppm (mean ± SD). Among the biological process GO categories, the microtubule polymerization category had the lowest average BMD (1.57 ± 0.66 ppm) followed by the response to xenobiotic stimulus (2.19 ± 1.29 ppm) and regulation of c-jun N-terminal kinase cascade (2.25 ± 1.48 ppm). Other GO categories associated with the presumed formaldehyde mode-of-action, such as the response to DNA damage, cell proliferation, and the inflammatory response, had higher average BMD values and were generally in the 6-7 ppm range (Table 3) . Among the molecular function GO categories, the subtilase activity group had the lowest average BMD (1.85 ± 0.15 ppm) followed by calcium-transporting ATPase activity (2.16 ± 1.07 ppm) and heat shock protein binding (2.17 ± 1.60 ppm).
DISCUSSION
The general methods employed in this study are all well established within their respective fields. BMD methods are regularly employed by the U.S. EPA for estimating reference doses and setting standards for noncancer human health effects (EPA, 1995) . Microarray technology has been broadly accepted as an efficient and reproducible way to simultaneously measure the expression of thousands of genes (Shi et al., 2006) . Finally, GO classification analysis has demonstrated broad applicability for grouping genes based on their cellular function (Beissbarth and Speed, 2004; Dennis et al., 2003; Khatri et al., 2004; Yu et al., 2006; Zhang et al., 2004) . In this study, the three tools were brought together in order to advance the application of genomic technologies in chemical risk assessment.
In combining the three tools, several challenges were encountered that require additional discussion. The first challenge was related to the selection of the BMR type based on the SD of the control animals. The BMR based on the SD was chosen under the assumption that the natural variation in expression for a particular gene could be characterized based on the control population. In other words, this natural variation would need to be exceeded in order to potentially observe an adverse effect. For example, if a gene is critical to cellular function and tightly regulated within a tissue, then the SD in the control animals would be relatively small. Conversely, less tightly regulated genes would have a higher SD in the control animals. Although the logic in selecting this BMR type is consistent with the underlying biology, the broad application of the approach across multiple chemicals and testing laboratories 244 poses significant challenges. In a testing environment, an increased variability in the control animals beyond that normally observed would artificially increase the BMD and BMDL estimates for the individual genes and the associated GO categories. Therefore, it could be potentially advantageous for a testing laboratory to maintain a stressed set of control animals. To overcome this limitation, the regulatory agencies would need to maintain a database of control gene expression values for the common test species and strains to ensure that the variability in expression was within normal bounds.
The second challenge posed in combining these tools was the selection of the BMR value itself. The proposed BMR was derived by assuming a normal distribution in control animals with adverse levels selected a priori to include 0.5% in each tail (1% total). A BMR of 1.349 times the estimated SD is the amount required to shift the mean response from that in the control distribution such that the treated distribution contains 11% in a single tail. Although other studies have also used a 10% shift in tail area (Crump, 1995; Gaylor and Slikker, 2004) , the BMR in their studies was based on a shift from a 1% area in a single tail for the control distribution to an 11% area in the treated distribution. In our study, we used two tails for the control distribution since we did not assume that we knew a priori in which direction the gene would change and we performed the BMD analysis in both adverse directions (i.e., increased and decreased expression) while selecting the direction with the lowest BMD.
The third challenge was the selection of the primary point of comparison across the various GO categories to represent the dose at which the specific cellular functions were altered. Three different values were considered-the minimum BMD, the BMD at the 10th percentile among all genes in the category, and the average BMD. The use of the minimum BMD as the point of comparison may hold certain appeal since it provides the most conservative estimate for selecting a reference dose. A fundamental biological question is whether the minimum BMD from the effect on a single gene really reflects the dose that can elicit a complex, adverse response such as cell proliferation or apoptosis. Several biological reasons argue against using the minimum BMD as the point of comparison. First, external stressors or perturbations cause changes in the expression of large batteries of genes, many within the same functional class, suggesting that complex biological process are altered through coordinate changes in the expression of families of genes (Currie et al., 2005; Hughes et al., 2000; Murray et al., 2004) . Second, complex biological systems are inherently robust against small perturbations (Kitano, 2004; Kitano and Oda, 2006) . Biological processes have evolved compensatory mechanisms that limit the effect of changes in a single gene. For example, the altered expression of an important gene such as a growth factor by a hypothetical toxicant would also elicit a feedback response within the pathway. A new steady state would be reached between the effects of the toxicant and the feedback mechanisms. The functional outcome for this The use of a percentile-based summary value is similar to the logic that underlies the benchmark methodology. In essence, the BMD at the 10th percentile for all genes in a GO category suggests that altering 10% of the genes is the threshold for producing the associated biological response. This may be a reasonable estimate for a GO category that represents a relatively detailed biological process, but as one proceeds through the GO hierarchy toward more general biological descriptions, a change in 10% of the genes would become increasing diluted through the addition of unaffected genes (e.g., MAPKKK cascade / protein kinase cascade / intracellular signaling cascade / signal transduction / cell communication / cellular process). One solution to this problem would be to vary the percentile depending on the level of the GO category within the hierarchy. However, this approach requires a relatively uniform amount of biological detail at each hierarchical level. Currently, the relative amount of detail is variable within the GO hierarchy, which makes 246 the percentile-based BMD less appealing as the point of comparison.
In the development of this method, the mean BMD was selected as the primary point of comparison based on its ability to reflect the aggregate behavior of genes within a GO category. For formaldehyde exposure, the mean BMD within several GO categories was closely associated with the phenotypic effects. A previous study has reported NOAEL and LOAEL values for epithelial hyperplasia of 2 and 6 ppm, respectively, for a 6-h exposure (Monticello et al., 1991) . The BMD 10% for the cell labeling index based on multiple time points has been calculated at 4.91 ppm . By comparison, the mean BMD value in our study for the positive regulation of cell proliferation was 5.68 ppm (Table 3 ). For the DNA damage response, the use of DNA-protein cross-links by formaldehyde has been proposed as a surrogate for mutagenicity . In a study by Casanova et al. (1994) , the DNAprotein cross-links in the rat nose was significantly increased beginning at 6 ppm following a 3-h exposure. In our study, the BMD value for the DNA damage response was 6.31 ppm (Table 1) . Overall, mean BMD values for the gene expression changes related to cell proliferation and the DNA damage response were both near 6 ppm and were comparable to the BMD 10% estimated for tumor formation of 6.40 ppm . The general concordance of these numbers suggests that the mean BMD provides the most appropriate summary value for the biological effects in this study. Moreover, in the absence of traditional histopathological and biochemical measurements, similar conclusions concerning the dosedependent effects may be reached using only the gene expression information. However, transcriptional changes do not necessarily equate with functional changes, and the results should be interpreted with an appropriate amount of caution.
Apart from the changes in cell proliferation and DNA damage, the gene expression studies also showed changes in microtubule-related processes between 1 and 2 ppm (Table 1) . These changes are consistent with the ability of formaldehyde to cross-link macromolecules . One possibility is that microtubule-related processes may be responding to cytoskeletal cross-links formed at the cell surface. Another possibility is that this category may be transcriptionally more active than other categories in response to multiple pathologies. Additional studies would have to be performed in order to directly link these effects to formaldehyde cross-links.
In conclusion, the development and broad availability of genomic tools continues to hold significant promise for the toxicology and risk assessment communities (Thomas et al., 2002; Travis et al., 2003) . The technology has the potential to transform chemical risk assessments through its ability to rapidly identify chemical hazards, reveal the underlying mechanism-of-action, and provide a better understanding of the dose-response behavior. However, despite the initial enthusiasm surrounding the technology, the risk assessment community has struggled to directly integrate them into the risk assessment process. The results from this study represents a significant step forward in applying genomic information to assessing health risks by both allowing a comprehensive survey of molecular and cellular changes associated with chemical exposure and providing the capability to identify reference doses at which cellular processes are altered.
SUPPLEMENTARY DATA
Supporting material is provided online and includes (1) Figure 1) . Supplementary data are available online at http:// toxsci.oxfordjournals.org/.
